NO943151D0 - Tilstedeværende suppresjon av autoimmune sykdommer - Google Patents

Tilstedeværende suppresjon av autoimmune sykdommer

Info

Publication number
NO943151D0
NO943151D0 NO943151A NO943151A NO943151D0 NO 943151 D0 NO943151 D0 NO 943151D0 NO 943151 A NO943151 A NO 943151A NO 943151 A NO943151 A NO 943151A NO 943151 D0 NO943151 D0 NO 943151D0
Authority
NO
Norway
Prior art keywords
suppression
autoantigens
autoimmune diseases
autoimmune disease
prophylactic
Prior art date
Application number
NO943151A
Other languages
English (en)
Other versions
NO943151L (no
NO319062B1 (no
Inventor
Howard L Weiner
Ariel Miller
Zhengri Zhang
Ahmad Al-Sabbagh
David A Hafler
Original Assignee
Autoimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Autoimmune Inc filed Critical Autoimmune Inc
Publication of NO943151D0 publication Critical patent/NO943151D0/no
Publication of NO943151L publication Critical patent/NO943151L/no
Publication of NO319062B1 publication Critical patent/NO319062B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Rehabilitation Therapy (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO19943151A 1992-02-28 1994-08-25 Bystander suppresjon av autoimmune sykdommer NO319062B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84375292A 1992-02-28 1992-02-28
PCT/US1993/001705 WO1993016724A1 (en) 1992-02-28 1993-02-25 Bystander suppression of autoimmune diseases

Publications (3)

Publication Number Publication Date
NO943151D0 true NO943151D0 (no) 1994-08-25
NO943151L NO943151L (no) 1994-10-26
NO319062B1 NO319062B1 (no) 2005-06-13

Family

ID=25290916

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19943151A NO319062B1 (no) 1992-02-28 1994-08-25 Bystander suppresjon av autoimmune sykdommer

Country Status (16)

Country Link
US (1) US20050208061A1 (no)
EP (1) EP0627933B1 (no)
JP (1) JP3712260B2 (no)
KR (1) KR950700082A (no)
AT (1) ATE228373T1 (no)
AU (2) AU3778593A (no)
BR (1) BR9306042A (no)
CA (1) CA2117492C (no)
DE (1) DE69332518T2 (no)
DK (1) DK0627933T3 (no)
ES (1) ES2190784T3 (no)
HU (1) HU220357B (no)
IL (1) IL104880A (no)
NO (1) NO319062B1 (no)
PT (1) PT627933E (no)
WO (1) WO1993016724A1 (no)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869054A (en) * 1987-06-24 1999-02-09 Autoimmune Inc. Treatment of multiple sclerosis by oral administration of autoantigens
US5571500A (en) * 1987-06-24 1996-11-05 Autoimmune, Inc. Treatment of autoimmune diseases through administration by inhalation of autoantigens
US5571499A (en) * 1987-06-24 1996-11-05 Autoimmune, Inc. Treatment of autoimmune diseases by aerosol administration of autoantigens
US5645820A (en) * 1987-06-24 1997-07-08 Autoimmune, Inc. Treatment of autoimmune diseases by aerosol administration of autoantigens
US5641474A (en) * 1987-06-24 1997-06-24 Autoimmune, Inc. Prevention of autoimmune diseases by aerosol administration of autoantigens
AU674584B2 (en) * 1993-06-02 1997-01-02 Tvw Telethon Institute For Child Health Research Cryptic peptides for use in inducing immunologic tolerance
BR9507452A (pt) * 1994-04-08 1997-08-05 Brigham & Womens Hospital Composição farmacêutica uso de um polipeptídeo não-interferon uso de uma quantidade de um antígeno padronizado e uma quantidade de um polipeptídeo não-interferon e produto contendo (1) uma quantidade de um antígeno padronizado e (11) uma quantidade de um polipeptídeo não-interferon
JPH09511745A (ja) * 1994-04-08 1997-11-25 ブリガム アンド ウィミンズ ホスピタル 経口寛容および／またはタイプｉインターフェロンを用いた自己免疫疾患の治療
AU4278296A (en) * 1994-10-25 1996-05-15 Immulogic Pharmaceutical Corporation Compositions and treatment for multiple sclerosis
US5856446A (en) * 1995-07-07 1999-01-05 Autoimmune Inc. Method of treating rheumatoid arthritis with low dose type II collagen
AU3225097A (en) * 1996-06-03 1998-01-05 Auragen, Inc. Immunotherapy for autoimmune disease
KR20000070460A (ko) * 1997-01-24 2000-11-25 왈리스 조 앤 메토트렉세이트와 공동으로 내성화를 사용한 자기면역질병의 치료
US7097845B2 (en) 1997-04-23 2006-08-29 Jacob Sten Petersen Combinations of antigen and mucosal binding component for inducing specific immunological tolerance
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6743427B1 (en) 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6710226B1 (en) 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
AU3896699A (en) * 1998-05-07 1999-11-23 Regents Of The University Of California, The Use of neglected target tissue antigens in modulation of immune responses
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
US7897575B2 (en) 2000-05-24 2011-03-01 The United States Of America As Represented By The Department Of Health And Human Services Treatment and prevention of vascular dementia
EP1842551A1 (en) * 2000-05-24 2007-10-10 The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services E-selectin for treating or preventing stroke
ATE367823T1 (de) * 2000-05-24 2007-08-15 Us Health E-selectin zur behandlung oder vorbeugung von schlaganfall
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
WO2004064863A1 (en) * 2003-01-23 2004-08-05 Lorantis Limited Treatment of autoimmune diseases using an activator for the notch signaling pathway
PE20050627A1 (es) 2003-05-30 2005-08-10 Wyeth Corp Anticuerpos humanizados que reconocen el peptido beta amiloideo
AR052051A1 (es) 2004-12-15 2007-02-28 Neuralab Ltd Anticuerpos ab humanizados usados en mejorar la cognicion
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
JP5889529B2 (ja) 2007-07-27 2016-03-22 ヤンセン・サイエンシズ・アイルランド・ユーシー アミロイド原性疾患の処置
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
EP2113560A1 (en) * 2008-04-28 2009-11-04 TXCell Compositions for treating an arthritic condition
PL219335B1 (pl) * 2008-07-04 2015-04-30 Inst Biotechnologii I Antybiotyków Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, jej zastosowanie oraz zawierająca ją kompozycja farmaceutyczna
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
WO2012049312A1 (en) * 2010-10-15 2012-04-19 Alk-Abelló A/S Suppression of a type 1 hypersensitivity immune response with an unrelated antigen
EP2627355B1 (en) * 2010-10-15 2015-08-26 ALK-Abelló A/S Suppression of a hypersensitivity immune response with unrelated antigen derived from allergen source material
CN110064049B (zh) 2012-06-21 2024-02-09 西北大学 肽缀合粒子
EP2928500B1 (en) 2012-12-04 2019-03-06 Phosphorex Inc. Microparticles and nanoparticles having negative surface charges
IL292823B2 (en) 2013-03-13 2023-11-01 Cour Pharmaceuticals Dev Company Secondary vaccine particles for the treatment of inflammation
MX2016001931A (es) 2013-08-13 2016-09-07 Univ Northwestern Particulas conjugadas con peptidos.
AU2016379413B2 (en) 2015-12-23 2024-04-04 Cour Pharmaceuticals Development Company Inc. Covalent polymer-antigen conjugated particles
JP2021523151A (ja) 2018-05-11 2021-09-02 ホスホレックス、インコーポレイテッド 負の表面電荷を有するマイクロ粒子及びナノ粒子

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4985436A (en) * 1984-02-17 1991-01-15 Arizona Board Of Regents Composition of matter for inhibiting leukemias and sarcomas
CA1302880C (en) * 1986-07-25 1992-06-09 Peter Koepff Agents for the treatment of arthroses
US5843445A (en) * 1987-06-24 1998-12-01 Autoimmune, Inc. Method of treating rheumatoid arthritis with type II collagen
US5869054A (en) * 1987-06-24 1999-02-09 Autoimmune Inc. Treatment of multiple sclerosis by oral administration of autoantigens
US5645820A (en) * 1987-06-24 1997-07-08 Autoimmune, Inc. Treatment of autoimmune diseases by aerosol administration of autoantigens
US5571499A (en) * 1987-06-24 1996-11-05 Autoimmune, Inc. Treatment of autoimmune diseases by aerosol administration of autoantigens
US5399347A (en) * 1987-06-24 1995-03-21 Autoimmune, Inc. Method of treating rheumatoid arthritis with type II collagen
US5571500A (en) * 1987-06-24 1996-11-05 Autoimmune, Inc. Treatment of autoimmune diseases through administration by inhalation of autoantigens
US5849298A (en) * 1987-06-24 1998-12-15 Autoimmune Inc. Treatment of multiple sclerosis by oral administration of bovine myelin
US5641474A (en) * 1987-06-24 1997-06-24 Autoimmune, Inc. Prevention of autoimmune diseases by aerosol administration of autoantigens
US5194425A (en) * 1988-06-23 1993-03-16 Anergen, Inc. Mhc-mediated toxic conjugates useful in ameliorating autoimmunity
DE69033487T2 (de) * 1989-12-20 2000-06-29 Autoimmune, Inc. Behandlung von autoimmunkrankheiten durch verabreichung von autoantigenen in form von aerosol
US5075112A (en) * 1990-02-12 1991-12-24 Cartilage Technologies Inc. Method of and dosage unit for inhibiting angiogenesis or vascularization in an animal using shark cartilage
WO1991012816A1 (en) * 1990-03-02 1991-09-05 Autoimmune, Inc. Enhancement of the down-regulation of autoimmune diseases by oral administration of autoantigens
ATE319474T1 (de) * 1990-10-15 2006-03-15 Autoimmune Inc Behandlung von autoimmunkrankheiten durch orale verabreichung von autoantigenen

Also Published As

Publication number Publication date
AU3778593A (en) 1993-09-13
WO1993016724A1 (en) 1993-09-02
ATE228373T1 (de) 2002-12-15
DK0627933T3 (da) 2003-03-24
DE69332518D1 (de) 2003-01-09
IL104880A (en) 1997-07-13
NO943151L (no) 1994-10-26
KR950700082A (ko) 1995-01-16
IL104880A0 (en) 1993-06-10
EP0627933B1 (en) 2002-11-27
CA2117492A1 (en) 1993-09-02
EP0627933A4 (en) 1997-01-15
PT627933E (pt) 2003-04-30
NO319062B1 (no) 2005-06-13
HU9402468D0 (en) 1994-10-28
JPH08504745A (ja) 1996-05-21
DE69332518T2 (de) 2003-09-04
AU3754297A (en) 1997-11-20
US20050208061A1 (en) 2005-09-22
ES2190784T3 (es) 2003-08-16
HUT74832A (en) 1997-02-28
HU220357B (hu) 2001-12-28
EP0627933A1 (en) 1994-12-14
BR9306042A (pt) 1997-11-18
AU720695B2 (en) 2000-06-08
JP3712260B2 (ja) 2005-11-02
CA2117492C (en) 2009-04-07

Similar Documents

Publication Publication Date Title
NO943151D0 (no) Tilstedeværende suppresjon av autoimmune sykdommer
KR930702026A (ko) 자기항원의 경구 투여에 의한 자기면역 질병의 치료
DE3854741D1 (de) Behandlung von autoimmun-erkrankungen durch orale verabreichung von autoantigenen.
BR9106114A (pt) Metodo para tratar ou prevenir uma doenca auto-imune (ad) e formulacao farmaceutica
EA200401473A1 (ru) Предотвращение и лечение амилоидогенного заболевания
ES2144398T3 (es) Tratamiento mejorado de enfermedades autoinmunes mediante la administracion en aerosol de autoantigenos.
NO960549L (no) Fremgangsmåte for modulering av den humane seksualrespons
PT668763E (pt) Utilizacao de fenserina para a preparacao de medicamentos para tratar doencas do conhecimento
ATE197670T1 (de) Parenterales busulfan zur behandlung von malignen krankheiten
MD1633B2 (en) Application of lysozyme dimer and method of non-specific cellular and humoral stimulation of mechanisms for immune system protection and for prophylaxis and treatment of immunodepressant state or diseases relating to it
MX9705198A (es) Metodos y formulaciones a base de colagena para el tratamiento de enfermedades mediadas por el sistema inmune.
EA199800941A1 (ru) Терапевтические средства, содержащие кислородные анион-радикалы и/или продукты их последующего превращения и расщепления, и их применение для лечения болезни паркинсона
RU94002713A (ru) Способ лечения детей с синдромом удлиненного интервала qт (романо-уорда)

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees